

Table S4: Association between wheeze phenotypes and wheeze 2 years later

Age at Baseline (years)	Age at Follow-up (years)	Phenotype at baseline	n (%)	Current wheeze at follow up Crude OR (95% CI)	Adj. OR* (95% CI)
ALSPAC					
2	4	No wheeze	681 (10.3)	1	1
		EVW	301 (47.2)	7.8 (6.5, 9.3)	3.7 (2.9, 4.6)
		MTW	448 (59.0)	12.5 (10.6, 14.8)	4.4 (3.5, 5.7)
4	6	No wheeze	348 (5.4)	1	1
		EVW	179 (40.6)	11.9 (9.5, 14.8)	3.4 (2.5, 4.7)
		MTW	435 (60.7)	26.6 (22.2, 32.1)	4.9 (3.5, 6.8)
LRC					
2	4	No wheeze	163 (11.1)	1	1
		EVW	56 (31.8)	3.7 (2.6, 5.3)	2.5 (1.6, 3.9)
		MTW	120 (55.3)	9.9 (7.2, 13.5)	4.0 (2.3, 7.1)
4	6	No wheeze	101 (6.9)	1	1
		EVW	36 (37.5)	8.1 (5.1, 12.8)	7.0 (4.1, 12.0)
		MTW	131 (61.5)	21.5 (15.3, 30.3)	13.6 (7.7, 24.0)

Abbreviations: ALSPAC Avon Longitudinal Study on Parents and Children, LRC Leicestershire Respiratory Cohort 1998-b, EVW episodic viral wheeze, MTW multiple trigger wheeze

* Adjusted for symptom severity at baseline (frequent attacks, shortness of breath, sleep disturbance, interference with activities and speech limitation)